Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intest Res. 2022;20(1):72-77.   Published online 2021 Feb 3     DOI: https://doi.org/10.5217/ir.2020.00117
Citations to this article as recorded by Crossref logo
Newer Immunosuppressants for Rheumatologic Disease
Ye Rin Koh, Kenneth C. Cummings
Anesthesiology Clinics.2024; 42(1): 131.     CrossRef
Peri-Operative Optimization of Patients with Crohn’s Disease
Hareem Syed, Ahmed Nadeem, David Gardinier, Kendra Weekley, Dovid Ribakow, Stephen Lupe, Shubha Bhat, Stefan Holubar, Benjamin L. Cohen
Current Gastroenterology Reports.2024;[Epub]     CrossRef
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study
Gabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, Fabiana Castiglione, Laura Melotti, Stefano Festa, Edoardo Vincenzo Savarino, Marie Truyens, Konstantinos Argyriou, Daniele Noviello, Tamas Molnar, Vincent Bouillon, Cristina Bezzio, Piotr Eder, Samuel
American Journal of Gastroenterology.2024;[Epub]     CrossRef
An update on the safety of long-term vedolizumab use in inflammatory bowel disease
Sailish Honap, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Expert Opinion on Drug Safety.2023; 22(9): 767.     CrossRef
Perioperative Management of Pediatric Crohn’s Disease
Brad Pasternak, Ashish Patel, Paul Tran, Lisa McMahon
Journal of Pediatric Gastroenterology & Nutrition.2023; 76(2): 137.     CrossRef
Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management
William J. Kane, Puja Shah Berry
Clinics in Colon and Rectal Surgery.2023; 36(03): 210.     CrossRef
Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
Shubha Bhat, Benjamin Click, Miguel Regueiro
Inflammatory Bowel Diseases.2023;[Epub]     CrossRef
Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Jihye Park
Intestinal Research.2022; 20(1): 1.     CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906.     CrossRef
Anti -TNFα agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era?
Caiguang Liu, Na Li, Shukai Zhan, Zhenyi Tian, Dongxuan Wu, Tong Li, Zhirong Zeng, Xiaojun Zhuang
Expert Opinion on Biological Therapy.2021; : 1.     CrossRef